Published on 10 Aug 2022 on Zacks via Yahoo Finance

Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?

Investors are always looking for stocks that are poised to beat at earnings season and Prelude Therapeutics Incorporated PRLD may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because for Prelude Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for PRLD in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 52 cents per share for PRLD, compared to a broader Zacks Consensus Estimate of a loss of 61 cents per share. This suggests that analysts have very recently bumped up their estimates for PRLD, giving the stock a Zacks Earnings ESP of +14.75% heading into earnings season.